Page 111 - CIBER-BBN2016-ENG

• Technological Platform on Nanomedicine.
The in vivo experimentation unit allows data to be obtained on the systemic behaviour of biomarkers (biodistribution, pharmacokinetics, pharmacodynamics, toxicity and therapeutic activity) using imaging techniques, combining invasive and non-invasive procedures.
This unit also enables nanomedicine-based therapies to be tested on conventional cell lines and primary cultures (loss and gain of function experiments and gene expression analysis, as well as studying control of expression at various levels: transcriptional [gene transfection, inducible systems], posttranscriptional [RNAi] and at the protein level [antagonists and antibody neutralization]).
Most relevant scientific articles
• Giannotti M.I., Abasolo I., Oliva M., Andrade F., García-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
• Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
• Gener P., De Sousa Rafael D.F., Fernández Y., Ortega J.S., Arango D., Abasolo I. et al. Cancer stem cells and personalized cancer nanomedicine. Nanomedicine. 2016;11(3):307-320.
• Andrade F., Fonte P., Costa A., Reis C.C., Nunes R., Almeida A. et al. Pharmacological and toxicological assessment of innovative self-Assembled polymeric micelles as powders for insulin pulmonary delivery. Nanomedicine. 2016;11(17):2305-2317.
• Uria N., Abramova N., Bratov A., Munoz-Pascual F.-X., Baldrich E. Miniaturized metal oxide pH sensors for bacteria detection. Talanta. 2016;147:364-369.
Highlights
We have developed new biosensors able to detect bacteria for biomedical applications from biological fluids by using miniaturized metal oxide base pH sensors. Further, we have also developed a new biological based system that allows in vitro/in vivo tracking of cancer stem cells. This system is based on bioluminiscent specific genetic vectors and is being used to develop new targeted drug delivery systems (DDS) as anticancer agents. A new DDS has been tested to improve sensitivity of cancer stem cells to chemotherapy with success. Finally, we together with other CIBER’s groups have also advance a specific DDS for enzyme replacement therapy for Fabry disease in cooperation with industrial partners. A GMP production pilot line is ongoing.
BBN
Research Groups 111